Tearsheet

Simulations Plus (SLP)

Market Price (12/27/2025): $18.775 | Market Cap: $377.9 Mil
Sector: Health Care | Industry: Health Care Technology

Simulations Plus (SLP)

Market Price (12/27/2025): $18.775
Market Cap: $377.9 Mil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%	Weak multi-year price returns 2Y Excs Rtn is -104%, 3Y Excs Rtn is -132%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 58x
1	Megatrend and thematic drivers Megatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more.		Weak revenue growth Rev Chg QQuarterly Revenue Change % is -6.5%
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
3			Key risks SLP key risks include [1] securities lawsuits, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%
1	Megatrend and thematic drivers Megatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more.
2	Weak multi-year price returns 2Y Excs Rtn is -104%, 3Y Excs Rtn is -132%
3	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 58x
4	Weak revenue growth Rev Chg QQuarterly Revenue Change % is -6.5%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
6	Key risks SLP key risks include [1] securities lawsuits, Show more.

Valuation, Metrics & Events

	12/27/25	2024	2023	2022
Share Price CYE	$18.77	$27.89	$44.56	$36.20
Market Cap CYE ($ Mil)	377.9	559.7	888.7	734.3
Total Debt ($ Mil)	0.6	0.6	1.0	1.2
Total Cash ($ Mil)	32.4	32.4	20.3	115.5
Enterprise Value ($ Mil)	346.2	560.3	889.7	735.5
Valuation Ratios
P/S TTM	4.8	7.1	12.8	12.3
P/EBIT TTM	58.2	86.4	145.9	79.6
P/E TTM	-5.8	-8.7	89.9	73.7
P/FCF TTM	26.2	38.9	99.2	41.8
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5

	12/27/25	2024	2023
Share Price CYE	$18.77	$27.89	$44.56
Market Cap CYE ($ Mil)	377.9	559.7	888.7
Total Debt ($ Mil)	0.6	0.6	1.0
Total Cash ($ Mil)	32.4	32.4	20.3
Enterprise Value ($ Mil)	346.2	560.3	889.7
Valuation Ratios
P/S TTM	4.8	7.1	12.8
P/EBIT TTM	58.2	86.4	145.9
P/E TTM	-5.8	-8.7	89.9
P/FCF TTM	26.2	38.9	99.2
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	SLP	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	0.1
Rev Chg Q	-6.5%	7.3%
Rev Chg LTM	13.1%	6.1%
Rev Chg 3Y Avg	13.7%	5.5%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	8.2%	18.8%
CFO/Rev LTM	22.9%	20.4%
Net Inc Mgn	-81.7%	13.1%
VALUATION	HIGH
P/S	4.8	3.3
P/CFO	20.8	15.8
P/FCF	26.2	20.7
P/E	-5.8	23.7
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.25	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Backlog	$20.4 million	2282025	Link
Average Software Revenue per Customer	$96,000	7142025	Link
Software Customer Renewal Rate (based on fees)	84%	7142025	Link
Software Customer Renewal Rate (based on accounts)	71%	7142025	Link

Upcoming
1/08/2026	Earnings Release	Rev: $18 Mil (E) EPS: $0.18 (E)
4/01/2026	Earnings Release	Rev: - EPS: -

SLP Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Here are five key points regarding Simulations Plus (SLP) from August 31, 2025, to December 27, 2025:

1. Simulations Plus reported a decline in its fourth-quarter fiscal 2025 revenues and adjusted earnings.

The company's adjusted earnings of 10 cents per share matched Zacks Consensus Estimate but were down from 18 cents in the prior-year quarter. Quarterly revenues decreased by 6% year-over-year to $17.5 million, matching consensus estimates. Software revenues, which constitute 52% of total quarterly revenues, plunged 9% year-over-year due to challenging market conditions and ongoing customer consolidation.

2. The company achieved 13% full-year revenue growth for fiscal 2025 despite fourth-quarter softness.

Despite the revenue pressure experienced in the fourth quarter, Simulations Plus met its revised fiscal 2025 guidance, delivering $79.2 million in revenues for the full fiscal year. This highlights its operational resilience and evolving product strategy.

3. Simulations Plus recorded a significant net loss for fiscal year 2025 due to a non-cash impairment charge.

For the full fiscal year 2025, the company reported a net loss of $64.7 million, or $3.22 diluted loss per share. This included a substantial non-cash impairment charge of $77.2 million.

4. The company reaffirmed its fiscal 2026 guidance, projecting low single-digit revenue growth.

Simulations Plus reiterated its fiscal 2026 revenue guidance, expecting it to be between $79 million and $82 million, which represents 0-4% year-over-year growth. They also reaffirmed adjusted diluted EPS guidance in the range of $1.03 to $1.10.

5. Simulations Plus highlighted its strategic pivot towards cloud, AI, and biologics modeling, aligning with FDA guidance.

Management noted accelerating demand for cloud deployment, AI-assisted workflows, and interoperability across modeling platforms, which are becoming essential for enterprise customers. The company also issued a press release in December highlighting how its technologies align with the FDA's new regulatory direction on streamlined nonclinical safety studies for monoclonal antibodies and announced ongoing investments in biologics modeling.

Stock Movement Drivers

Fundamental Drivers

The 26.0% change in SLP stock from 9/26/2025 to 12/26/2025 was primarily driven by a 28.0% change in the company's P/S Multiple.

	9262025	12262025	Change
Stock Price ($)	14.89	18.76	25.99%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	80.38	79.18	-1.50%
P/S Multiple	3.73	4.77	28.00%
Shares Outstanding (Mil)	20.11	20.13	-0.07%
Cumulative Contribution			25.99%

LTM = Last Twelve Months as of date shown

Market Drivers

9/26/2025 to 12/26/2025

	Return	Correlation
SLP	26.0%
Market (SPY)	4.3%	25.0%
Sector (XLV)	15.2%	16.3%

Fundamental Drivers

The 11.3% change in SLP stock from 6/27/2025 to 12/26/2025 was primarily driven by a 10.6% change in the company's P/S Multiple.

	6272025	12262025	Change
Stock Price ($)	16.86	18.76	11.27%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	78.56	79.18	0.78%
P/S Multiple	4.31	4.77	10.58%
Shares Outstanding (Mil)	20.10	20.13	-0.15%
Cumulative Contribution			11.27%

LTM = Last Twelve Months as of date shown

Market Drivers

6/27/2025 to 12/26/2025

	Return	Correlation
SLP	11.3%
Market (SPY)	12.6%	26.4%
Sector (XLV)	17.0%	25.5%

Fundamental Drivers

The -34.8% change in SLP stock from 12/26/2024 to 12/26/2025 was primarily driven by a -42.1% change in the company's P/S Multiple.

	12262024	12262025	Change
Stock Price ($)	28.78	18.76	-34.82%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	70.01	79.18	13.09%
P/S Multiple	8.23	4.77	-42.09%
Shares Outstanding (Mil)	20.03	20.13	-0.48%
Cumulative Contribution			-34.82%

LTM = Last Twelve Months as of date shown

Market Drivers

12/26/2024 to 12/26/2025

	Return	Correlation
SLP	-34.8%
Market (SPY)	15.8%	20.0%
Sector (XLV)	13.3%	20.0%

Fundamental Drivers

The -48.6% change in SLP stock from 12/27/2022 to 12/26/2025 was primarily driven by a -65.2% change in the company's P/S Multiple.

	12272022	12262025	Change
Stock Price ($)	36.52	18.76	-48.63%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	53.91	79.18	46.88%
P/S Multiple	13.72	4.77	-65.23%
Shares Outstanding (Mil)	20.24	20.13	0.57%
Cumulative Contribution			-48.64%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2023 to 12/26/2025

	Return	Correlation
SLP	-58.5%
Market (SPY)	48.0%	22.1%
Sector (XLV)	18.2%	21.0%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
SLP Return	149%	-34%	-22%	23%	-37%	-31%	-32%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
SLP Win Rate	67%	33%	33%	50%	42%	50%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
SLP Max Drawdown	-8%	-48%	-23%	-8%	-39%	-55%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See SLP Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	SLP	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-62.7%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	168.3%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-31.3%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	45.5%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	35 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-30.4%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	43.6%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	113 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-89.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	864.4%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	2,394 days	1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Simulations Plus's stock fell -62.7% during the 2022 Inflation Shock from a high on 2/9/2021. A -62.7% loss requires a 168.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Simulations Plus (SLP)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

AI Analysis | Feedback

Here are 1-3 brief analogies for Simulations Plus (SLP):

Adobe for drug discovery and development: SLP provides essential, specialized software tools for pharmaceutical and biotech professionals, much like Adobe does for creative professionals.
Autodesk for pharmaceutical research: Similar to Autodesk's role in providing design and modeling software for engineers and architects, SLP offers powerful simulation tools for scientists in drug development.

AI Analysis | Feedback

GastroPlus™: A leading physiologically-based pharmacokinetic (PBPK) modeling and simulation software used to predict drug absorption, distribution, metabolism, and excretion.
ADMET Predictor™: Cheminformatics software that leverages machine learning to predict physicochemical and ADMET properties of drug candidates directly from their chemical structures.
DILIsym®: Mechanistic modeling software designed to simulate and assess the risk of drug-induced liver injury (DILI) for new compounds.
NAFLDsym®: Mechanistic modeling software used to simulate the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), aiding in therapeutic development.
MonolixSuite™: A comprehensive suite of software tools for population pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation, essential for analyzing clinical trial data.

AI Analysis | Feedback

Simulations Plus (SLP) Major Customers

Simulations Plus (SLP) primarily sells its software and consulting services to other companies and institutions, operating on a business-to-business (B2B) model rather than directly to individuals.

According to its most recent annual filings, including the 10-K for the fiscal year ended August 31, 2023, no single customer accounted for 10% or more of Simulations Plus's consolidated net revenues. This indicates that the company has a diversified customer base rather than relying on a few specific "major customers" that would require individual disclosure. Therefore, specific names of major customer companies with their symbols cannot be provided.

However, Simulations Plus broadly serves the following categories of organizations:

Pharmaceutical Companies: Large and small pharmaceutical firms utilizing SLP's software for drug discovery, development, and regulatory submissions.
Biotechnology Companies: Biotech firms focused on developing new therapeutic products, often leveraging SLP's modeling and simulation tools.
Academic Institutions and Research Centers: Universities and research organizations that use the company's platforms for scientific research and education.
Government Agencies: Regulatory bodies and public health organizations that employ SLP's solutions for various research and assessment purposes.

AI Analysis | Feedback

Amazon.com, Inc. (AMZN)

AI Analysis | Feedback

Shawn O'Connor, Chief Executive Officer

Mr. O'Connor has served as Chief Executive Officer of Simulations Plus since 2018. Prior to joining Simulations Plus, he was President, Chief Executive Officer, and Director at Entelos, Inc. from 2011 to 2018. From 2002 to 2009, Mr. O'Connor served as Chairman, President, and Chief Executive Officer at Pharsight Corporation, where he developed a software product strategy that resulted in a 20x increase in valuation. His earlier career included roles as Chief Financial Officer at Diasonics Ultrasound, Inc. from 1988 to 1994, and President, Chief Operating Officer, and Chief Financial Officer at QRS Corp. from 1995 to 2000.

Will Frederick, Chief Financial Officer and Chief Operating Officer

Mr. Frederick was appointed Chief Financial Officer of Simulations Plus in December 2020, and assumed the additional role of Chief Operating Officer in January 2024. He brings over 25 years of financial leadership experience to the company, with a proven track record in driving revenue growth, increasing profitability, and managing merger and acquisition activities. His global experience spans both publicly traded and privately held companies, including Pharsight, Entelos, Avaya, The Walt Disney Company, and Ford Motor Company. Notably, he previously served as CFO at Pharsight and Entelos during the periods when Shawn O'Connor was CEO of those companies.

Walter S. Woltosz, Board Member

Mr. Woltosz is a cofounder of Simulations Plus and served as its Chief Executive Officer until June 2018. He has been a director of the company since June 1996, and was Chairman of the Board from July 1996 to December 2024. In 1981, he established Words+, Inc., a company specializing in computer-based communication systems, including the system famously used by Professor Stephen Hawking. The initial capital for Simulations Plus originated from a settlement Mr. Woltosz received related to the development of an ADA assistive device.

Viera Lukacova, Chief Science Officer

Dr. Lukacova is the Chief Science Officer at Simulations Plus and has been with the company for approximately 15 years. She is instrumental in working on the company's GastroPlus®, DDDPlus™, and MembranePlus™ software packages and contributes to modeling studies that assist companies with their drug development programs. Her expertise lies in mechanistic absorption and PBPK modeling, and she holds a Ph.D. in Pharmaceutical Sciences.

John A. DiBella, Chief Revenue Officer

Mr. DiBella serves as the Chief Revenue Officer for Simulations Plus, a position he assumed effective May 30, 2025. He has been with the company since 2003, and prior to his current role, he served as the Business Unit President for PBPK and Cheminformatics Solutions.

AI Analysis | Feedback

The key risks to Simulations Plus's business are multifaceted, stemming from recent financial and governance challenges, ongoing profitability concerns, and the inherent competitive dynamics of its industry.

Securities Lawsuits, Governance Issues, and Acquisition-Related Impairments: Simulations Plus is currently embroiled in multiple class-action lawsuits alleging securities fraud. These legal challenges follow a significant non-cash impairment charge of $77.2 million related to the Pro-ficiency acquisition, which also contributed to a substantial stock price plunge and an auditor change. These issues indicate serious financial, reputational, and governance risks, raising questions about the company's M&A strategy and internal controls.
Declining Margins and Profitability Challenges: Despite demonstrating revenue growth, Simulations Plus has faced significant declines in its gross and net margins, as well as its operating profit margin. This points to potential cost management issues and challenges in translating revenue expansion into sustained profitability. The shift in business mix, potentially influenced by acquisitions with lower gross margins, has been identified as a factor contributing to this margin pressure.
Competitive Pressures and Market Conditions: The company operates within a competitive healthcare software industry. It faces competition from existing players and the evolving risk of clients developing their own in-house artificial intelligence (AI) solutions for drug discovery. Furthermore, Simulations Plus has encountered "significant headwinds" due to broader market uncertainties in the biopharma sector, including funding constraints, drug pricing pressures, and potential tariffs, leading to reduced client spending, project cancellations, and delays.

AI Analysis | Feedback

The rapid advancement and adoption of integrated Artificial Intelligence (AI) and Machine Learning (ML) platforms for drug discovery and development pose a clear emerging threat. These platforms, either developed by AI-first drug discovery companies (e.g., Insilico Medicine, Recursion Pharmaceuticals) or as sophisticated in-house capabilities within large pharmaceutical companies, aim to automate and optimize various stages of drug research, including predictive modeling and simulation. This trend could potentially reduce the reliance on external, specialized software vendors for specific modeling tasks that Simulations Plus currently provides, as these capabilities become more integrated into broader AI-driven workflows.

AI Analysis | Feedback

For Simulations Plus (SLP), the addressable markets for their main products and services are as follows:

Biosimulation Market: The global biosimulation market was valued at approximately USD 4.24 billion in 2024 and is projected to reach USD 9.18 billion by 2029.
In-Silico Drug Discovery Market: The global in-silico drug discovery market was valued at USD 3.6 billion in 2024 and is projected to reach USD 6.8 billion by 2030. North America accounted for the largest revenue share of 40.5% in 2024.
Clinical Trial Simulation Tools Market: The global clinical trial simulation tools market was estimated at USD 1.47 billion in 2024 and is expected to reach USD 2.91 billion by 2032.
PBPK Modeling and Simulation Software Market: The global PBPK modeling and simulation software market size was valued at US$ 363.5 million in 2024 and is estimated to grow to US$ 926.5 million by 2030.
Quantitative Structure-Activity Relationship (QSAR) Market: The global Quantitative Structure-Activity Relationship (QSAR) market size was USD 1,658.6 million in 2024 and is projected to reach USD 2,493.9 million by 2031. North America held over 40% of the global revenue with a market size of USD 663.44 million in 2024.

AI Analysis | Feedback

Simulations Plus (SLP) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market trends:

Strategic Acquisitions and Integration: The successful integration and ongoing contributions from recent acquisitions, notably Pro-ficiency, are anticipated to fuel revenue growth. For instance, Pro-ficiency contributed significantly to total revenue in fiscal year 2024 and is expected to continue to do so in fiscal year 2025, particularly within the medical communications and adaptive learning and insights business units. The company's strategy includes combining organic growth with strategic acquisitions to expand its product line and address evolving drug development needs.
Advancements and Expansion of Core Software Products: Growth in core software platforms like GastroPlus, ADMET Predictor, and MonolixSuite is a consistent driver. The company is continuously enhancing these products with new features and capabilities, such as the launch of ADMET Predictor 13 with improved predictive power and the upcoming upgrade of GastroPlus with enhanced AI capabilities. The recent launch of GastroPlus X.2, which introduces AI-powered tools on the S+ Cloud platform, further exemplifies this.
Integration of AI and Cloud Technologies: Simulations Plus is committed to rolling out a series of new AI-driven initiatives and developing cloud platforms across its product suite. This focus on AI and cloud integration is expected to drive future growth and innovation by enhancing the usefulness and applications of model-informed drug development.
Expanding Services Revenue, particularly Medical Communications: While some service areas have faced headwinds, the Medical Communications business unit (acquired through Pro-ficiency) has been a primary driver of services revenue growth. The company is optimizing its business unit structure to enhance customer engagement and accelerate cross-selling opportunities for its biosimulation solutions.
Increased Adoption of Biosimulation in Drug Development and Regulatory Acceptance: The broader market trend of increased demand for biosimulation software and services is a significant driver. Regulatory bodies, such as the FDA, are increasingly promoting computer modeling over animal testing, as highlighted by the FDA Modernization Act 2.0. This shift positions Simulations Plus's software and consulting services for long-term relevance and growth by improving drug candidate selection, accelerating clinical development, and streamlining regulatory approval.

AI Analysis | Feedback

Share Repurchases

Simulations Plus authorized a $50 million share repurchase program on December 29, 2022.
In January 2023, the company executed a $20 million accelerated share repurchase agreement.
Following the accelerated share repurchase, $30 million remained available under the authorized repurchase program.

Share Issuance

The number of shares outstanding was approximately 19,967,077 as of December 27, 2023.
As of June 30, 2025, Simulations Plus had approximately 20.1 million shares outstanding.
The number of shares outstanding was approximately 20.13 million as of November 4, 2025.

Inbound Investments

Simulations Plus received an undisclosed amount in a Grant (prize money) funding round on November 13, 2024, with investors including the FDA, NIH, and HHS.
In the fiscal year ended August 31, 2024, the company participated in nine funded grants from the U.S. Food and Drug Administration (FDA) aimed at enhancing PBPK modeling science.

Outbound Investments

In June 2024, Simulations Plus acquired Pro-ficiency Holdings Inc. for approximately $100 million in cash, which significantly expanded its reach across the drug development value chain and doubled its addressable market.
Simulations Plus acquired Immunetrics in June 2023 for $15.5 million.
The company made one acquisition in 2020.

Capital Expenditures

Simulations Plus' fiscal year 2024 capital expenditures (ending August 31, 2024) were $1.0 million.
Capital expenditures for fiscal year 2023 (ending August 31, 2023) were $0.9 million.
The company's capital expenditures for fiscal year 2022 (ending August 31, 2022) were $1.1 million.

Better Bets than Simulations Plus (SLP)

INDUSTRY: Health Care Technology

Higher Rev Chg 3Y Avg | Lower P/S (Values for SLP: 13.7% | 4.8x)

PHR (21.0% | 2.2x)

Phreesia

OMDA (37.9% | 4.0x)

Omada Health

TALK (22.1% | 2.8x)

Talkspace

WEAV (19.0% | 2.4x)

Higher Rev Chg 3Y Avg | Lower P/S (Values for SLP: 13.7% | 4.8x)

GMED (45.6% | 4.3x)

Globus Medical

BMRN (15.5% | 3.7x)

BioMarin Pharmaceutical

ENSG (18.4% | 2.1x)

Ensign

HIMS (71.0% | 3.5x)

Hims & Hers Health

BTSG (24.3% | 0.6x)

BrightSpring Health Services

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for SLP: 13.7% | 58.2x)

LLY (23.4% | 42.3x)

Eli Lilly

BSX (15.6% | 38.3x)

Boston Scientific

VEEV (14.1% | 42.9x)

Veeva Systems

DXCM (17.3% | 38.6x)

DexCom

UTHR (19.0% | 14.6x)

United Therapeutics

Higher Rev Chg LTM (Value for SLP: 13.1%)

LLY (36.8%)

Eli Lilly

ISRG (22.2%)

Intuitive Surgical

BSX (21.6%)

Boston Scientific

CI (20.9%)

Cigna

MCK (17.2%)

McKesson

Higher Rev Chg 3Y Avg (Value for SLP: 13.7%)

ALNY (51.4%)

Alnylam Pharmaceuticals

LLY (23.4%)

Eli Lilly

INSM (22.8%)

Insmed

ISRG (16.3%)

Intuitive Surgical

BSX (15.6%)

Boston Scientific

Higher Op Mgn LTM (Value for SLP: 8.2%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

ABBV (24.1%)

AbbVie

TMO (18.4%)

Thermo Fisher Scientific

Higher CFO/Rev LTM (Value for SLP: 22.9%)

AMGN (36.5%)

Amgen

ABBV (35.0%)

AbbVie

ISRG (30.8%)

Intuitive Surgical

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

Higher FCF/Rev LTM (Value for SLP: 18.2%)

ABBV (33.0%)

AbbVie

AMGN (32.1%)

Amgen

ISRG (23.6%)

Intuitive Surgical

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

Higher Total Yield (Value for SLP: -17.1%)

MRK (10.2%)

Merck

UNH (8.5%)

UnitedHealth

JNJ (7.5%)

Johnson & Johnson

ABBV (3.4%)

AbbVie

LLY (1.9%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for SLP: 13.7% | 4.8x)

BRK-B (19.8% | 2.7x)

Berkshire Hathaway

UBER (19.6% | 3.4x)

Uber Technologies

PGR (20.6% | 1.6x)

Progressive

MELI (39.5% | 3.9x)

MercadoLibre

APO (89.3% | 3.2x)

Apollo Asset Management

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for SLP: 13.7% | 58.2x)

NVDA (91.6% | 42.1x)

NVIDIA

META (17.3% | 20.4x)

Meta Platforms

GE (15.7% | 37.0x)

GE Aerospace

MU (28.3% | 23.3x)

Micron Technology

BKNG (17.8% | 19.6x)

Booking

Higher Rev Chg LTM (Value for SLP: 13.1%)

NVDA (65.2%)

NVIDIA

AVGO (23.9%)

Broadcom

META (21.3%)

Meta Platforms

MSFT (15.6%)

Microsoft

GOOGL (13.4%)

Alphabet

Higher Rev Chg 3Y Avg (Value for SLP: 13.7%)

NVDA (91.6%)

NVIDIA

PLTR (29.3%)

Palantir Technologies

AVGO (25.2%)

Broadcom

BRK-B (19.8%)

Berkshire Hathaway

META (17.3%)

Meta Platforms

Higher Op Mgn LTM (Value for SLP: 8.2%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

AMZN (11.4%)

Amazon.com

Higher CFO/Rev LTM (Value for SLP: 22.9%)

META (56.8%)

Meta Platforms

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

Higher FCF/Rev LTM (Value for SLP: 18.2%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

META (23.7%)

Meta Platforms

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

Higher Total Yield (Value for SLP: -17.1%)

MSFT (3.6%)

Microsoft

GOOGL (3.5%)

Alphabet

AMZN (2.9%)

Amazon.com

AAPL (2.8%)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	SLP	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-5.8	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	58.2	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	-6.5%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	13.1%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	13.7%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	20.2%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Simulations Plus Earnings Notes
2	Would You Still Hold Simulations Plus Stock If It Fell 30%?	Return
3	SLP Dip Buy Analysis
4	Day 11 of Loss Streak for Simulations Plus Stock with -39% Return (vs. -39% YTD) [6/23/2025]
5	Now Is Not The Time To Buy Simulations Plus Stock	Buy or Fear
6	Day 10 of Loss Streak for Simulations Plus Stock with -38% Return (vs. -38% YTD) [6/20/2025]	Notification
7	Day 9 of Loss Streak for Simulations Plus Stock with -35% Return (vs. -35% YTD) [6/18/2025]	Notification
8	Day 8 of Loss Streak for Simulations Plus Stock with -34% Return (vs. -34% YTD) [6/17/2025]	Notification
9	Day 7 of Loss Streak for Simulations Plus Stock with -32% Return (vs. -32% YTD) [6/16/2025]	Notification
10	Simulations Plus Market Price	Market Price

	Title
0	ARTICLES

Trade Ideas

Select ideas related to SLP. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%
SLP_8312022_Quality_Momentum_RoomToRun_10%	08312022	SLP	Simulations Plus	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	-36.1%	-25.5%	-41.7%
SLP_8312020_Quality_Momentum_RoomToRun_10%	08312020	SLP	Simulations Plus	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	22.8%	-25.4%	-29.2%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Simulations Plus

Peers to compare with:

Financials

	SLP	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Simulati.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	18.76	23.26	24.49	305.09	78.16	273.40	51.32
Mkt Cap	0.4	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	79	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	6	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	14	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	14	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	18	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	18	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	SLP	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Simulati.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	13.1%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	13.7%	-3.9%	6.5%	2.6%	3.7%	1.8%	3.2%
Rev Chg Q	-6.5%	4.2%	14.4%	9.1%	7.5%	9.6%	8.3%
QoQ Delta Rev Chg LTM	-1.5%	1.1%	3.7%	2.1%	1.8%	2.1%	2.0%
Op Mgn LTM	8.2%	6.6%	4.8%	17.7%	22.5%	31.9%	12.9%
Op Mgn 3Y Avg	10.8%	7.4%	7.2%	16.4%	24.2%	30.8%	13.6%
QoQ Delta Op Mgn LTM	2.4%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	22.9%	6.7%	8.5%	20.6%	23.8%	26.6%	21.8%
CFO/Rev 3Y Avg	26.2%	6.8%	12.7%	21.4%	26.1%	28.4%	23.8%
FCF/Rev LTM	18.2%	5.1%	1.8%	18.1%	22.1%	23.5%	18.2%
FCF/Rev 3Y Avg	20.2%	5.5%	4.6%	18.6%	24.6%	25.6%	19.4%

Valuation

	SLP	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Simulati.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	0.4	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	4.8	0.4	1.0	4.4	5.4	10.0	4.6
P/EBIT	58.2	6.8	19.9	25.1	22.5	31.3	23.8
P/E	-5.8	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	20.8	5.9	11.2	21.1	22.5	37.5	21.0
Total Yield	-17.1%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	2.8%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.0	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	-0.1	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	SLP	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Simulati.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	8.5%	-1.8%	14.4%	0.6%	2.7%	-1.5%	1.7%
3M Rtn	26.0%	-11.9%	2.7%	7.9%	17.0%	7.1%	7.5%
6M Rtn	11.3%	-4.0%	34.5%	6.6%	15.2%	36.3%	13.2%
12M Rtn	-34.8%	-27.3%	14.2%	39.2%	33.7%	6.0%	10.1%
3Y Rtn	-48.6%	-3.8%	67.7%	139.0%	79.5%	113.4%	73.6%
1M Excs Rtn	7.1%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	21.7%	-16.2%	-1.7%	3.6%	12.7%	2.8%	3.2%
6M Excs Rtn	-1.0%	-16.3%	22.3%	-5.7%	3.0%	24.0%	1.0%
12M Excs Rtn	-49.8%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	-4.6%
3Y Excs Rtn	-132.1%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

Comparison Analyses

	Title
0	Simulations Plus vs. LSI Industries: With Return Forecast Of 51%, Simulations Plus Is A Better Bet
1	Simulations Plus vs. Coty: With Return Forecast Of 51%, Simulations Plus Is A Better Bet
2	Simulations Plus vs. Cinedigm Digital Cinema: With Return Forecast Of 53%, Simulations Plus Is A Better Bet
3	Simulations Plus vs. XpresSpa Group: With Return Forecast Of 555%, XpresSpa Group Is A Better Bet
4	Simulations Plus vs. MEI Pharma: With Return Forecast Of 82%, MEI Pharma Is A Better Bet
5	Simulations Plus vs Varex Imaging: Similar Market Cap; Which Stock Is A Better Bet?
6	Simulations Plus vs Sorrento Therapeutics: Similar Revenue; Which Stock Is A Better Bet?
7	Simulations Plus vs Intellia Therapeutics: Similar Revenue; Which Stock Is A Better Bet?
8	Simulations Plus vs HealthEquity: Similar Income; Which Stock Is A Better Bet?
9	Simulations Plus vs nVent Electric plc: Similar Income; Which Stock Is A Better Bet?

FDIC Bank Data

$ Mil \| FY: 8/31	LTM	2025	2024	2023	2022	2021	2020
Period End	8/31/2025	8/31/2025	8/31/2024	8/31/2023	8/31/2022	8/31/2021	8/31/2020
Filing Date	12/1/2025	12/1/2025	10/30/2024	10/27/2023	10/28/2022	10/27/2021	11/16/2020
Key Financials
Total Revenue	79	79	70	60	54	46	42
EBITDA	15	15	12	13	18	15	14
Operating Income	6	6	6	9	15	11	12
Net Income	-65	-65	10	10	12	10	9
EPS	-3.22	-3.22	0.50	0.50	0.62	0.49	0.52
Growth Rates
Total Revenue Growth	13.1%	13.1%	17.5%	10.5%	16.0%	11.7%	22.4%
EBITDA Growth	24.6%	24.6%	-9.7%	-29.3%	25.8%	2.4%	7.8%
Operating Income Growth	5.9%	5.9%	-33.5%	-38.1%	32.5%	-3.0%	9.0%
Net Income Growth	-750.2%	-750.2%	-0.1%	-20.2%	27.6%	4.8%	8.7%
Margins
EBITDA Margin	18.6%	18.6%	16.8%	21.9%	34.3%	31.6%	34.5%
Operating Income Margin	8.2%	8.2%	8.8%	15.5%	27.7%	24.2%	27.9%
Net Income Margin	-81.7%	-81.7%	14.2%	16.7%	23.2%	21.1%	22.4%
Cash & Debt
Total Cash	32	32	20	115	128	124	116
Total Debt	1	1	1	1	1	1	1
Net Debt / (Cash)	-32	-32	-19	-114	-127	-122	-115
Cash Flows
Net Cash from Operations	18	18	13	22	18	19	11
Free Cash from Operations	14	14	9	18	14	15	8
Returns to Shareholders
Dividends	0	-0	5	5	5	5	4
Share Repurchases	-0	-0	-0	20	-0	-0	-0

$ Mil \| FY: 8/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	8/31/2025	5/31/2025	2/28/2025	11/30/2024	8/31/2024	5/31/2024	2/29/2024	11/30/2023	8/31/2023	5/31/2023	2/28/2023	11/30/2022
Filing Date	12/1/2025	7/15/2025	4/4/2025	1/8/2025	10/30/2024	7/8/2024	4/5/2024	1/5/2024	10/27/2023	7/7/2023	4/7/2023	1/6/2023
Key Financials Quarterly
Total Revenue	17	20	22	19	19	19	18	14	16	16	16	12
Ebitda	2	5	5	2	1	3	6	2	1	5	5	2
Operating Income	1	3	3	0	-1	2	4	1	0	4	4	1
Net Income	-1	-67	3	0	1	3	4	2	1	4	4	1
EPS	-0.03	-3.35	0.15	0.01	0.04	0.16	0.20	0.10	0.03	0.20	0.21	0.06
Key Financials TTM
Total Revenue TTM	79	80	79	74	70	67	65	62	60	56	54	53
Ebitda TTM	15	14	12	12	12	12	14	13	13	13	14	16
Operating Income TTM	6	5	4	5	6	7	10	9	9	10	11	12
Net Income TTM	-65	-63	7	8	10	10	11	11	10	10	10	11
Growth Rates Quarterly
Total Revenue Growth	-6.5%	9.8%	22.5%	30.5%	19.4%	14.2%	16.2%	21.2%	33.2%	8.5%	6.4%	-3.6%
EBITDA Growth	90.8%	69.0%	-10.1%	16.6%	-15.8%	-37.7%	11.6%	13.9%	-18.8%	-13.5%	-23.3%	-61.2%
Operating Income Growth	157.3%	59.3%	-38.9%	-86.9%	-632.9%	-54.1%	10.1%	9.3%	-68.9%	-17.2%	-26.4%	-76.8%
Net Income Growth	-180.8%	-2245.9%	-23.7%	-89.4%	57.9%	-21.7%	-3.5%	56.2%	-44.4%	-1.9%	-5.3%	-58.9%
Margins Quarterly
EBITDA Margin	11.5%	26.1%	22.2%	12.6%	5.7%	16.9%	30.3%	14.1%	8.0%	31.1%	31.5%	15.1%
Operating Income Margin	3.8%	14.7%	12.1%	0.7%	-6.2%	10.1%	24.3%	6.6%	1.4%	25.2%	25.6%	7.3%
Net Income Margin	-3.9%	-330.6%	13.7%	1.1%	4.5%	16.9%	22.0%	13.4%	3.4%	24.7%	26.5%	10.4%
Cash & Debt
Total Cash	32	28	21	18	20	119	109	114	115	122	115	132
Total Debt	1	1	1	1	1	1	1	1	1	1	1	1
Net Debt / (Cash)	-32	-28	-21	-17	-19	-118	-107	-113	-114	-121	-114	-130
Cash Flows Quarterly
FCF from Operations	6	8	6	-1	2	6	6	0	3	9	6	5
Cash Flows TTM
FCF from Operations TTM	18	14	12	12	13	15	18	17	22	27	22	19
Returns to Shareholders Quarterly
Dividends	0	0	0	0	1	1	1	1	1	1	1	1
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	2.1%	8.4%	7.0%	0.3%	-3.4%	18.9%	33.4%	9.2%	2.8%	60.1%	56.8%	27.5%
Return on Invested Capital (ROIC) TTM
ROIC TTM	4.8%	3.3%	2.2%	3.1%	3.7%	19.4%	19.8%	23.7%	25.7%	36.4%	38.1%	101.6%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Software	41	37	33	28
Services	29	23	21	19
Cognigen Corporation					11
DILIsym Services, Inc.					7
Lixoft					2
Simulations Plus, Inc.					22
Total	70	60	54	46	42

Price Behavior

Price Behavior

Market Price	$18.76
Market Cap ($ Bil)	0.4
First Trading Date	06/19/1997
Distance from 52W High	-49.3%
	50 Days	200 Days
DMA Price	$17.89	$20.37
DMA Trend	down	up
Distance from DMA	4.8%	-7.9%
	3M	1YR
Volatility	53.4%	68.0%
Downside Capture	53.39	129.99
Upside Capture	153.82	68.40
Correlation (SPY)	25.5%	20.0%

SLP Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.28	0.99	0.86	1.29	0.68	0.91
Up Beta	1.16	2.04	2.13	2.06	0.94	1.01
Down Beta	-0.69	1.54	1.71	1.69	-0.07	0.41
Up Capture	11%	95%	63%	-14%	44%	56%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	11	23	33	58	116	361
Down Capture	26%	23%	-28%	184%	119%	107%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	9	19	28	65	129	383

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of SLP With Other Asset Classes (Last 1Y)
	SLP	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-34.4%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.3%
Annualized Volatility	67.6%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	-0.33	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		19.9%	19.9%	3.5%	5.7%	17.3%	24.7%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of SLP With Other Asset Classes (Last 5Y)
	SLP	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-20.9%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	51.1%	14.5%	17.1%	15.5%	18.7%	18.9%	48.7%
Sharpe Ratio	-0.26	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		29.1%	34.3%	5.6%	6.8%	30.6%	20.9%

Based On 10-Year Data

		Comparison of SLP With Other Asset Classes (Last 10Y)
	SLP	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	8.3%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	48.1%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.35	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		32.3%	34.7%	3.8%	9.0%	27.2%	13.7%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	1,149,138
Short Interest: % Change Since 11302025	-12.2%
Average Daily Volume	427,113
Days-to-Cover Short Interest	2.69
Basic Shares Quantity	20,128,000
Short % of Basic Shares	5.7%

Returns Analyses

	Title
0	Would You Still Hold Simulations Plus Stock If It Fell 30%?
1	Simulations Plus Stock Return Comparison
2	[10/5/2021] Simulations Plus (SLP) Stock Price Forecast: AI Forecasts SLP Stock Price To Be Around $40.4 In A Month (Up 1.9%)
3	Simulations Plus Total Shareholder Return (TSR): 36.1% in 2022 and 19.0% 3-yr returns (above peer average)

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
10/22/2025	13.2%	17.7%	4.9%
7/14/2025	-25.8%	-24.8%	-18.8%
4/3/2025	7.8%	8.1%	41.1%
1/7/2025	-7.2%	-1.8%	19.4%
10/23/2024	-8.9%	-15.6%	-11.6%
7/2/2024	-14.9%	-18.0%	-14.5%
10/25/2023	-14.7%	-11.0%	1.6%
7/6/2023	1.6%	13.7%	22.7%
...
SUMMARY STATS
# Positive	8	9	8
# Negative	10	9	10
Median Positive	7.8%	8.0%	21.0%
Median Negative	-11.7%	-14.3%	-10.9%
Max Positive	13.2%	19.7%	41.1%
Max Negative	-25.8%	-24.8%	-18.8%

	Forward Returns
10/22/2025	13.2%	17.7%	4.9%
7/14/2025	-25.8%	-24.8%	-18.8%
4/3/2025	7.8%	8.1%	41.1%
1/7/2025	-7.2%	-1.8%	19.4%
10/23/2024	-8.9%	-15.6%	-11.6%
7/2/2024	-14.9%	-18.0%	-14.5%
10/25/2023	-14.7%	-11.0%	1.6%
7/6/2023	1.6%	13.7%	22.7%
4/5/2023	1.1%	8.0%	-2.2%
1/4/2023	-7.1%	4.0%	13.6%
10/26/2022	-14.5%	-13.3%	-12.9%
7/6/2022	7.9%	7.5%	29.4%
4/6/2022	6.9%	7.3%	-10.3%
1/6/2022	8.7%	2.2%	-9.8%
10/25/2021	10.8%	19.7%	25.3%
7/12/2021	-17.5%	-14.3%	-10.0%
4/12/2021	-4.1%	-1.6%	-10.5%
11/17/2020	-8.3%	-18.1%	-11.4%
SUMMARY STATS
# Positive	8	9	8
# Negative	10	9	10
Median Positive	7.8%	8.0%	21.0%
Median Negative	-11.7%	-14.3%	-10.9%
Max Positive	13.2%	19.7%	41.1%
Max Negative	-25.8%	-24.8%	-18.8%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
8312025	12012025	10-K 8/31/2025
5312025	7152025	10-Q 5/31/2025
2282025	4042025	10-Q 2/28/2025
11302024	1082025	10-Q 11/30/2024
8312024	10302024	10-K 8/31/2024
5312024	7082024	10-Q 5/31/2024
2292024	4052024	10-Q 2/29/2024
11302023	1052024	10-Q 11/30/2023
8312023	10272023	10-K 8/31/2023
5312023	7072023	10-Q 5/31/2023
2282023	4072023	10-Q 2/28/2023
11302022	1062023	10-Q 11/30/2022
8312022	10282022	10-K 8/31/2022
5312022	7082022	10-Q 5/31/2022
2282022	4082022	10-Q 2/28/2022
11302021	1072022	10-Q 11/30/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Simulations Plus (SLP)

Market Price (12/27/2025): $18.775 | Market Cap: $377.9 MilSector: Health Care | Industry: Health Care Technology

Simulations Plus (SLP)

Market Price (12/27/2025): $18.775Market Cap: $377.9 MilSector: Health CareIndustry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

SLP Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Simulations Plus (SLP)

Simulations Plus (SLP) Major Customers

Interactive Breakdown

Better Bets than Simulations Plus (SLP)

INDUSTRY: Health Care Technology

Higher Rev Chg 3Y Avg | Lower P/S (Values for SLP: 13.7% | 4.8x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for SLP: 13.7% | 58.2x)

Higher Rev Chg LTM (Value for SLP: 13.1%)

Higher Rev Chg 3Y Avg (Value for SLP: 13.7%)

Higher Op Mgn LTM (Value for SLP: 8.2%)

Higher CFO/Rev LTM (Value for SLP: 22.9%)

Higher FCF/Rev LTM (Value for SLP: 18.2%)

Higher Total Yield (Value for SLP: -17.1%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for SLP: 13.7% | 4.8x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for SLP: 13.7% | 58.2x)

Higher Rev Chg LTM (Value for SLP: 13.1%)

Higher Rev Chg 3Y Avg (Value for SLP: 13.7%)

Higher Op Mgn LTM (Value for SLP: 8.2%)

Higher CFO/Rev LTM (Value for SLP: 22.9%)

Higher FCF/Rev LTM (Value for SLP: 18.2%)

Higher Total Yield (Value for SLP: -17.1%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for SLP: 13.7% | 4.8x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for SLP: 13.7% | 58.2x)

Higher Rev Chg LTM (Value for SLP: 13.1%)

Higher Rev Chg 3Y Avg (Value for SLP: 13.7%)

Higher Op Mgn LTM (Value for SLP: 8.2%)

Higher CFO/Rev LTM (Value for SLP: 22.9%)

Higher FCF/Rev LTM (Value for SLP: 18.2%)

Higher Total Yield (Value for SLP: -17.1%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Simulations Plus

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Market Price (12/27/2025): $18.775 | Market Cap: $377.9 Mil
Sector: Health Care | Industry: Health Care Technology

Market Price (12/27/2025): $18.775
Market Cap: $377.9 Mil
Sector: Health Care
Industry: Health Care Technology